N
KYMR icon

Natixis’s Kymera Therapeutics KYMR Stock Holding History

Natixis’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,595
Closed -$113K – 1149
2025
Q2 		$113K Sell
2,595
-10,079
-80% -$347K ﹤0.01% 826
2025
Q1 		$356K Buy
+12,674
New +$462K ﹤0.01% 696
2024
Q2 		– Sell
-1,979
Closed -$79.6K – 1078
2024
Q1 		$79.6K Sell
1,979
-1,992
-50% -$71.3K ﹤0.01% 793
2023
Q4 		$101K Sell
3,971
-209
-5% -$3.74K ﹤0.01% 773
2023
Q3 		$58.1K Buy
+4,180
New +$84K ﹤0.01% 814
2022
Q2 		– Sell
-8,803
Closed -$373K – 1268
2022
Q1 		$373K Sell
8,803
-8,345
-49% -$352K ﹤0.01% 1028
2021
Q4 		$1.09M Sell
17,148
-38,991
-69% -$2.27M ﹤0.01% 907
2021
Q3 		$3.3M Buy
56,139
+49,575
+755% +$2.87M 0.01% 634
2021
Q2 		$318K Buy
+6,564
New +$285K ﹤0.01% 779

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Natixis's KYMR Position: Q3 2025 in Review

Natixis sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 2,595 shares — an estimated $113K sold.

Natixis first reported a position in KYMR in Q2 2021 and held it in 9 quarters. The position peaked at $3.3M in Q3 2021. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Natixis reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Natixis sold 2,595 Kymera Therapeutics shares in Q3 2025, an estimated $113K.
  • Natixis first reported a position in Kymera Therapeutics in Q2 2021 and held it in 9 quarters.
  • Natixis's Kymera Therapeutics position peaked at $3.3M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.